FDA approves expanded indication for Lilly’s Jaypirca
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company's Jaypirca (pirtobrutinib) as…
05 Oct 2026
Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US
Bayer has announced plans to invest $2.2bn in a new pharmaceutical manufacturing facility in Ohio, US. The facility will be constructed in the New Albany International Business Park. This investment…
02 Oct 2026
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
AstraZeneca and Daiichi Sankyo have partnered with Summit Therapeutics to explore the potential of their co-developed antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), alongside Summit’s in-licensed candidate, ivonescimab. Through this collaboration,…
02 Oct 2026
Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal
Novartis has become the latest big pharma player to bet on the bispecific T-cell engager (BiTE) modality by inking a multi-billion dollar autoimmune-focused deal with Chinese biotech Abogen Biosciences. As…
01 Oct 2026
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their pipeline horizon – the companies have agreed to expand their…
01 Oct 2026
Varda pockets $251m to back space-based pharma processing mission
Varda Space Industries has banked $251m in a Series D financing to scale its in-space pharmaceutical processing operations, as the industry increasingly recognises the potential of producing drugs in microgravity…
01 Oct 2026
Bristol Myers Squibb secures expanded US approval for Camzyos
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric…